MoonLake Immunotherapeutics (MLTX) Current Leases (2022 - 2026)

MoonLake Immunotherapeutics' Current Leases history runs 5 years deep, the most recent figure standing at $920000.0 for Q1 2026.

• In Q1 2026, Current Leases fell 35.75% year-over-year to $920000.0; the TTM figure through Mar 2026 stood at $920000.0 (down 35.75% YoY), while the FY2025 annual figure was $1.2 million, down 10.06% from the prior year.
• Current Leases for Q1 2026 stood at $920000.0, down from $1.2 million in the prior quarter.
• The five-year high for Current Leases was $1.5 million in Q2 2025, with the low at $153629.0 in Q4 2022.
• The 5-year median for Current Leases is $1.3 million (2024), against an average of $992805.9.
• The sharpest annual moves came in 2024 and 2026: Current Leases jumped 824.21% in 2024, then tumbled 35.75% in 2026.
• MoonLake Immunotherapeutics' Current Leases stood at $153629.0 in 2022, then soared by 679.72% to $1.2 million in 2023, then rose by 14.54% to $1.4 million in 2024, then fell by 10.06% to $1.2 million in 2025, then fell by 25.45% to $920000.0 in 2026.
• Business Quant data shows MLTX's Current Leases at $920000.0 in Q1 2026, $1.2 million in Q4 2025, and $1.5 million in Q3 2025.